



**PRESS RELEASE - February, 2008**

**The University hospital in Maastricht, the Netherlands, has temporarily suspended an intensive care probiotics study with a product from Probi.**

The decision was made when it became clear that another study in Utrecht, the Netherlands, with no links to Probi or Probi's probiotics, demonstrated a higher than expected mortality in patients with acute pancreatitis. Acute pancreatitis is a rare disease and is considered life threatening.

The probiotics were administered with tubes into the patient's small intestines. The study was coordinated by the Utrecht University Medical Center, using a mix of six probiotic strains never used by Probi and that were supplied by a local company. The cause of the higher than expected mortality in the Utrecht study is still unclear and there are currently no links to the probiotics. As a matter of precaution the study with Probi's product has temporarily been suspended, awaiting the Utrecht investigation.

"The study in Maastricht with Probi's product is different from the Utrecht study. Probi's study is only designed to test the effects of probiotics in order to prevent bacterial infections in patients that already suffer from impaired immune systems. It is not designed to prevent an acute phase or to treat patients already in an acute condition," says Probi's CEO Michael Oredsson.

"As a matter of precaution, and despite the fact that the conditions for the studies are different, the Maastricht study was also put on hold until we are certain that there are no obstacles to proceed," Mr. Oredsson adds.

Probi's probiotics have been tested in more than 25 studies on humans and have been consumed by millions of people without any reported side effects.

**For further information, contact:**

Michael Oredsson, President, tel: +46 (0)46-286 89 23 or +46-707-18 89 30, e-post: michael.oredsson@probi.se

Todd Beckman, COO, tel: +1 303 241 5481, e-mail: todd.beckman@nextfoods.net

--More--

**About Probi**

Probi is a leading probiotic research and development company based in Sweden. Research is carried out using living micro-organisms with scientifically proven health effects. The main research areas are: stomach and gastrointestinal tracts, immune defense, risk factors for cardiovascular diseases, stress and recovery. Probi's business concept is based on offering efficient and well-documented probiotic product. Probi's customers include leading companies in the functional foods, dietary supplements and clinical nutrition marketing areas. Probi's shares are listed on the Nordic Exchange. For further information, visit [www.probi.se](http://www.probi.se).